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Abstract
Background: Co-infection with herpes simplex virus type 2 (HSV-2) has been associated with increased HIV-1 RNA levels and
immune activation, two predictors of HIV-1 progression. The impact of HSV-2 on clinical outcomes among HIV-1 infected
pregnant women is unclear.
Methods: HIV-1 infected pregnant women in Nairobi were enrolled antenatally and HSV-2 serology was obtained. HIV-1
RNA and CD4 count were serially measured for 12–24 months postpartum. Survival analysis using endpoints of death,
opportunistic infection (OI), and CD4,200 cells mL, and linear mixed models estimating rate of change of HIV-1 RNA and
CD4, were used to determine associations between HSV-2 serostatus and HIV-1 progression.
Results: Among 296 women, 254 (86%) were HSV-2-seropositive. Only 30 (10%) women had prior or current genital ulcer
disease (GUD); median baseline CD4 count was 422 cells mL. Adjusting for baseline CD4, women with GUD were significantly
more likely to have incident OIs (adjusted hazard ratio (aHR) 2.79, 95% CI: 1.33–5.85), and there was a trend for association
between HSV-2-seropositivity and incident OIs (aHR 3.83, 95% CI: 0.93–15.83). Rate of change in CD4 count and HIV-1 RNA
did not differ by HSV-2 status or GUD, despite a trend toward higher baseline HIV-1 RNA in HSV-2-seropositive women (4.73
log10 copies/ml vs. 4.47 log10 copies/ml, P=0.07).
Conclusions: HSV-2 was highly prevalent and pregnant HIV-1 infected women with GUD were significantly more likely to
have incident OIs than women without GUD, suggesting that clinically evident HSV-2 is a more important predictor of HIV-1
disease progression than asymptomatic HSV-2.
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Introduction
HIV-1 and herpes simplex virus type 2 (HSV-2) co-infection
presents important implications during pregnancy for women and
their children. Prior studies in HIV-1 infected pregnant women
have demonstrated associations between HSV-2 and genital ulcers
and perinatal HIV-1 transmission [1,2,3,4], and co-infected women
have increased genital shedding of HIV-1 [5]. Women with HIV-1
in developing countries have increased morbidity in pregnancy and
postpartum [6], and more perinatal complications than HIV-1-
seronegative women [7,8]. Addressing the implications of HSV-2
infectioninpregnancy and postpartummaybea tooltoimprovethe
health of HIV-1 infected mothers and their infants.
HSV-2 co-infection has been associated with increased
heterosexual acquisition [9] and transmission [10] of HIV-1,
increased levels of cellular immune activation [11], and elevated
HIV-1 viral loads [12,13]. Antivirals targeting HSV-2 are low cost,
safe, and well-tolerated, making them attractive novel therapeutic
tools. Multiple short randomized trials of acyclovir or valacyclovir
in co-infected patients have shown 0.25 to 0.5 log10 copies/ml
reductions in HIV-1 viral load [10,14,15,16,17,18,19]. A multisite
randomized controlled trial of daily acyclovir in over 3,000 HIV-
1-seropositive, HSV-2-seropositive African adults demonstrated
that HSV-2 suppression not only produced a sustained reduction
in HIV-1 viral load over a 2-year period in participants on
acyclovir [10], but also reduced risk of HIV-1 disease progression
events by 16% when compared to placebo [20]. Suppression of
HSV-2 with acyclovir or valacyclovir has been hypothesized as a
strategy to mitigate the consequences of chronic HIV-1 infection
in sub-Saharan Africa, where more than 80% of people with HIV-
1 are HSV-2-seropositive. However, HIV-1 infected pregnant
women have been excluded from trials of HSV-2 suppression.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19947To evaluate associations between HSV-2 and HIV-1 disease in
pregnant and postpartum women, we conducted a retrospective
cohort study to determine the effect of HSV-2 serostatus and
GUD on HIV-1 disease progression in HIV-1 infected pregnant
women followed for 12 to 24 months after delivery.
Methods
Study setting and population
HIV-1-seropositive pregnant women in Nairobi, Kenya were
recruited from Nairobi City Council clinics and enrolled into a
prospective cohort study of immunological markers, morbidity and
infant feeding practices, as described previously [3]. The first 216
women, enrolled between 1999 and 2002, were followed for 12
months; the remaining 319 women, enrolled between 2002 and
2005, were followed for 24 months.
Ethics
Written informed consent was obtained from all study subjects
in the cohort. Human experimentation guidelines from the US
Department of Health and Human Services were followed. Ethical
approvals were obtained from the institutional review board of the
University of Washington and the ethics review committee of
Kenyatta National Hospital (KNH) and the Kenya Medical
Research Institute (KEMRI).
Clinical procedures
Women were followed during pregnancy and postpartum with
regular physical exams, and plasma samples were taken at
postpartum months 1, 3, 6, 9, and 12, and then quarterly for
those followed during the second postpartum year. At enrollment,
a pelvic exam was done and the presence of any ulcer was
recorded. Women were classified as having genital ulcer disease
(GUD) if they had either reported having a history of an ulcer
prior to enrollment or had an ulcer observed during the exam at
enrollment. All women were screened for syphilis, the other main
cause of GUD in this population, with baseline rapid plasma
reagin (RPR) testing, and treated if positive. The following
opportunistic infections (OIs) were recorded: incident pulmonary
or extrapulmonary tuberculosis, herpes zoster, Pneumocystis jirovecii
pneumonia (PCP), Kaposi’s sarcoma (KS), meningitis or enceph-
alitis. These diagnoses were made in study clinic or were
abstracted from records of hospitalized participants.
Women were provided zidovudine (ZDV) prophylaxis accord-
ing to standard prevention of mother-to-child transmission
(PMTCT) protocols in Kenya at that time, which included short
courses of ZDV beginning at 34–36 weeks gestation through
delivery. Women with CD4 counts#200 cells/ml received co-
trimoxazole prophylaxis per Kenyan guidelines during the study
period and were referred for highly-active antiretroviral therapy
(HAART), although access to HAART in Kenya remained limited
until 2003. Consistent with clinical practice in Kenya at the time,
acyclovir was not used for treatment of GUD, but some women
received it for severe herpes zoster.
Laboratory methods
Cryopreserved plasma samples from the date of study
enrollment were identified from women in the cohort. HSV-2
antibody was detected using HSV-2 enzyme-linked immunosor-
bency assays (ELISA) (HerpeSelect, Focus Diagnostics, Cypress,
CA, USA), performed at University of Washington in 2007 (first
175 specimens) and University of Nairobi in 2009 (remaining 124
specimens). A cutoff index value $3.5 was used to determine a
positive result. In Seattle, positive and equivocal results were
repeated with Western blot testing and participants were
considered positive if Western blot testing was positive. In Nairobi,
Western blot testing was not done but samples with indeterminate
results were re-tested; if a result remained indeterminate, the
participant was excluded from analysis. CD4 count was measured
in Nairobi with a FACScan flow cytometer (BD Biosciences, San
Jose, CA USA), with semiannual proficiency testing performed.
Plasma HIV-1 RNA levels were quantified at the Fred Hutchinson
Cancer Research Center in Seattle using a transcription-mediated
amplification assay (Gen-Probe, San Diego, CA USA), which has
been validated to quantify prevalent HIV-1 subtypes in Kenya
[21]. Maternal plasma was tested for syphilis at enrollment using
the rapid plasma reagin (RPR) (Becton Dickinson, Cockeysville,
MD) and confirmed using the Treponema pallidum hemagglutination
assay (Randox Laboratories Ltd, Ardmore, Crumlin, UK).
Statistical methods
To determine baseline correlates of HSV-2-seropositivity in the
cohort, univariate analyses were performed using Chi-squared,
Fisher’s exact test, and Student t-tests. Maternal HIV-1 disease
progression was defined using three separate endpoints: death,
CD4#200 cells/ml, and first OI. Participants were censored after
the first occurrence of an event. The following combined outcomes
were also evaluated: 1) death or CD4#200 cells/ml, 2) death or
OI, and 3) death, CD4#200 cells/ml or OI. Cumulative incidence
was estimated using the Kaplan-Meier curves. Associations
between disease progression and baseline risk factors were assessed
using Cox proportional hazards regression, adjusted for baseline
CD4 count. Data were also censored if any of the following
occurred: death, start of HAART, or second pregnancy.
To estimate rates of change of postpartum CD4 count and
HIV-1 RNA levels, linear mixed effects models with random
slopes were constructed. HIV-1 RNA levels and CD4 counts
during pregnancy were excluded from linear mixed effects models.
A locally weighted scatterplot smoother was applied to scatterplots
of CD4 and plasma HIV-1 RNA level. Stata Version 10.0 (College
Station, Texas USA) software was used for statistical analysis.
Results
Study population
Of the 535 women in the original cohort, 299 women had
baseline plasma samples available for HSV-2 antibody assays.
HSV-2 serostatus was ascertained for 296 women; their charac-
teristics are summarized in Table 1. Baseline characteristics of
women with HSV-2 serology results were similar to the
characteristics of all women in the original cohort (data not
shown) [22]. The median age of women was 25 years and 95%
were married or partnered. Of those with HSV-2 serology results,
254 (86%) were HSV-2-seropositive and 30 (10%) had prior or
current GUD. Nineteen (6%) women reported GUD prior to
enrollment and all were also HSV-2-seropositive. Ten women
(3%) were diagnosed with syphilis at baseline; only one woman
with serologic syphilis had an observed or reported ulcer; verifying
that most genital ulcers in our cohort were due to HSV-2. Median
baseline CD4 count was 422 cells/ml and 12% of women had
CD4#200 cells/ml.
Mean follow-up was 18 months, during which time 19 deaths
occurred; 17 among HSV-2-seropositive women (hazard ratio
[HR] 1.33, 95% confidence interval [CI]: 0.32–6.05). OIs were
identified in 45 (15%) women, including 28 with tuberculosis, 16
with herpes zoster, 4 with meningitis, 2 with PCP and one with
KS. Six (2%) women had more than one OI during follow-up;
only the first OI was used for analysis.
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Only HSV-2-seropositive women reported a history of GUD (8%
vs. 0% of HSV-2-seronegative women, P=0.05)andtheytendedto
be more likely to have a CD4 count#200 cells/mla tb a s e l i n e
compared to HSV-2-seronegative women (13% vs. 5%, P=0.14).
There was also a trend for higher mean baseline HIV-1 log10 viral
loads among HSV-2-seropositive women (4.73 log10 copies/ml vs.
4.46 log10 copies/ml, P=0.07). Reported history of sexually
transmitted infection (STI) was similar in both groups (12% vs.
13%, P=0.79), and there was no differenceinage, parity, or number
of lifetime sexual partners between HSV-2-seropositive and seroneg-
ative women (P.0.05 for all) (Table 1). All 30 women in the study
withGUDwerealsoHSV-2-seropositiveandhadsimilarSTIhistory,
syphilis prevalence, baseline CD4 counts and HIV-1 log10 viral loads
when compared to women without GUD (Table 1). Of those with
GUD, 13 women (5%) had an ulcer seen at the baseline exam.
HSV-2-seropositivity, GUD, and HIV-1 disease progression
There was a trend toward an association between HSV-2-
seropositivity and incident OI; 17% of the HSV-2-seropositive
women had an incident OI during follow-up, compared to 5% of
the HSV-2-seronegative women (HR 3.66, 95% CI: 0.88–15.11,
P=0.07) (Figure 1). In a model adjusted for baseline CD4, the
relationship between HSV-2-seropositivity and OI persisted
(Adjusted HR (aHR) 3.83, 95% CI: 0.93–15.83, P=0.06)
(Table 2). Progression to CD4#200 cells/ml was similar between
HSV-2-seropositive and seronegative women (HR 1.15, 95% CI:
0.52–2.53, P=0.74), and changes in plasma HIV-1 RNA did not
differ significantly by HSV-2 serostatus (Figure 2). HSV-2
serostatus did not show a significant effect on rates of change in
CD4; the average rate of change of CD4 cells/ml/month was
23.42 cells/ml/month in the HSV-2-seronegative group and
24.22 cells/ml/month in the HSV-2-seropositive group (P=0.57).
GUD was found to be significantly associated with incident OIs
(HR 2.42, 95% CI: 1.16–5.02, P=0.02) (Figure 3), and this
relationship strengthened after adjusting for baseline CD4 (aHR
2.79, 95% CI: 1.33–5.85, P=0.007) (Table 2). Nearly one-third
(30%) of the women with GUD had an OI during follow-up,
compared with only 14% of the women who had not experienced
GUD. The rate of change of HIV-1 RNA was similar for women
with and without GUD. The rate of decline of CD4 count was
24.34 cells/ml/month for those without GUD vs. 22.34 cells/ml/
month for those with GUD, but this difference was not statistically
significant (P=0.25).
Discussion
In this cohort of 296 pregnant and postpartum women in
Kenya, we evaluated HIV-1 disease progression in HSV-2 co-
infected participants. Women with GUD were more likely to
experience an OI during the follow-up period, and this
relationship persisted after controlling for CD4 count at study
entry. HSV-2-seropositive women also exhibited this trend toward
more OIs.
HSV-2-seropositive women with genital ulcers may differ from
co-infected women with asymptomatic HSV-2; and this difference
cannot be explained by CD4 count alone. It is possible that
symptomatic genital ulcers may identify co-infected persons with
different immunologic characteristics from those who are
seropositive for HSV-2 but do not develop or recognize GUD.
Our study is not the first to observe the importance of GUD as a
possible marker of HIV-1 disease progression. In both incident
and prevalent HIV-1 infection, patients in Rakai, Uganda with
GUD were noted to have higher plasma viral loads than those who
were HSV-2-seropositive without GUD, an effect which persisted
after stratifying by disease stage [23]. A study of a cohort of 1,938
HIV-1/HSV-2 co-infected women in the Women’s Interagency
Health Study (WIHS) noted that women with GUD had modest
increases in plasma HIV-1 viral load over time, as well as lower
CD4 counts, when compared with asymptomatic women, even
after adjusting for baseline CD4 counts [24]. Chronic antiviral
Table 1. Characteristics of HIV-1 Infected Women at Enrollment, and by HSV-2 Antibody Status or GUD.
Median value (IQR)
Or (N) % Mean or N (%) Mean or N (%) P-value
Mean or N
(%)
Mean or N
(%) P-value
Characteristic All women N=296
HSV-2-seropositive
N=254
HSV-2-seronegative
N=42
Ever GUD
N=30
Never GUD
N=266
Age (years) 25 (22–28) 25.5 25.2 0.77 26.2 25.3 0.37
Parity* 1 (1–2) 1.5 1.4 0.64 1.7 1.5 0.52
Lifetime number of sex partners 3 (2–4) 3.4 2.5 0.13 3.1 3.3 0.80
History of STI 39 (13%) 34 (13%) 5 (12%) 0.79 5 (17%) 34 (13%) 0.55
Syphilis at enrollment** 10 (3%) 10 (4%) 0 (0) 0.21 1 (3%) 9 (3%) 0.73
History of GUD 19 (6%) 19 (8%) 0 (0) 0.05 - - -
GUD on exam 13 (4%) 12 (5%) 0 (0) 0.13 - - -
Ever GUD 30 (10%) 30 (12%) 0 (0) 0.01 - - -
HSV-2-seropositive 254 (86%) - - - 30 (100%) 0 (0%) 0.02
Baseline CD4 (cells/ml)
# 422 (288–617) 465 467 0.96 458 466 0.86
CD4#200 cells/ml
# 35 (12%) 33 (13%) 2 (5%) 0.14 4 (13%) 31 (12%) 0.83
Baseline log10 HIV-1 RNA level
# 4.75 (4.22–5.31) 4.73 4.46 0.07 4.82 4.68 0.40
Methods: Chi-squared or Fisher’s exact test for dichotomous variables and t-test for continuous variables.
GUD=genital ulcer disease. IQR=interquartile range. STI=sexually transmitted infection.
*N=293,
**N=294,
#N=288.
doi:10.1371/journal.pone.0019947.t001
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of HIV-1 infected patients in several randomized trials [25,26,27]
and one meta-analysis [28].
While acyclovir therapy has been shown to have clinical and
virological benefits for co-infected HIV-1-seropositive adults (both
with and without symptomatic disease), it has not been studied
during pregnancy and postpartum. Our analysis was motivated by
the hypothesis that demonstrating increased HIV-1 disease
progression in co-infected women during pregnancy and postpar-
tum could provide a rationale for HSV-2 antiviral therapies as an
adjunct treatment for HIV-1. Our results suggest that women with
GUD are a subgroup that may benefit from anti-herpes treatment
or prophylaxis. Furthermore, using GUD to determine eligibility
for implementation of anti-herpes treatment would eliminate the
barrier of diagnostic testing for HSV-2 seropositivity. Lingappa
et al showed a 16% reduction in HIV-1 disease progression for
HIV-1/HSV-2 co-infected adults when using acyclovir for herpes
suppression. It is also possible that during pregnancy and
postpartum, anti-HSV-2 therapy may provide additional suppres-
sion of HIV-1 viral load, and could add to interventions to prevent
transmission of HIV-1 to infants.
Our study had several strengths and limitations. Women in this
pre-HAART cohort were closely monitored for illness and
laboratory markers of disease progression, experienced high rates
of morbidity and mortality [6], and there was minimal loss to
follow-up. Low numbers of HSV-2-seronegative women, however,
limited our power to detect associations between HSV-2
seropositivity and dichotomous outcomes such as mortality or
CD4 count#200 cells/ml. Using the risk estimate of HR=0.84
reported by Lingappa et al [20] for the effect of acyclovir on similar
dichotomous outcomes, a sample size of at least 2,000 participants
would be required to show a similar result. Thus, our sample
lacked statistical power to definitively exclude an association
between HSV-2 serostatus and HIV-1 disease progression in
Figure 1. Risk of Opportunistic Infection, by HSV-2 Serostatus (Kaplan-Meier Estimates). Opportunistic infection is defined as: first
episode of herpes zoster, Pneumocystis jirovecii pneumonia, tuberculosis, Kaposi sarcoma, meningitis, or encephalitis. Relative risk calculated using
Cox regression. Time=months since delivery.
doi:10.1371/journal.pone.0019947.g001
Table 2. Risk of Postpartum HIV-1 Progression Event by HSV-2 Serostatus and GUD.
Event Total events (%) aHR* 95% CI P-value
HSV-2-seropositive
N=254
HSV-2- seronegative
N=42
Death 17 (7%) 2 (5%) 19 (6%) 1.39 0.32–6.05 0.66
CD4#200 cells/ml 50 (20%) 7 (17%) 57 (19%) 1.16 0.52–2.56 0.72
Opportunistic Infection 43 (17%) 2 (5%) 45 (15%) 3.83 0.93–15.83 0.06
Any GUD N=30 No GUD N=266
Death 3 (10%) 16 (6%) 19 (6%) 1.17 0.33–4.08 0.80
CD4#200 cells/ml 6 (20%) 51 (19%) 57 (19%) 0.63 0.26–1.49 0.29
Opportunistic Infection 9 (30%) 36 (14%) 45 (15%) 2.79 1.33–5.85 0.007
GUD=genital ulcer disease; CI=Confidence interval; aHR=Adjusted hazard ratio.
*adjusted for Baseline CD4 count.
Opportunistic infection is defined as: herpes zoster, Pneumocystis jirovecii pneumonia, tuberculosis, Kaposi sarcoma, meningitis, encephalitis.
doi:10.1371/journal.pone.0019947.t002
HSV-2, Genital Ulcers & HIV-1 Progression in Women
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19947postpartum women. However, by evaluating change in quantita-
tive measures of CD4 and HIV-1 RNA over time, power was
enhanced.
Limitations in our analysis include the challenges of identifying
prior and current GUD, due to symptoms of varying severity.
Women may not have recalled prior GUD at study entry. Incident
ulcers were not systematically assessed, therefore we were unable
to include the impact of incident ulcers in our analysis. Also, there
was possible miscategorization of HSV-2-seronegative women
who were at ongoing risk of acquiring HSV-2 infection and may
have seroconverted during follow-up.
In summary, this study demonstrates an increased incidence of
OIs among pregnant and postpartum women with HSV-2
infection and GUD. A randomized clinical trial in Kenya of
HSV-2 suppression in pregnant and postpartum women with
HIV-1 and HSV-2 co-infection was recently concluded; this trial
Figure 3. Risk of Opportunistic Infection, by GUD (Kaplan-Meier Estimates). Opportunistic infection is defined as: first episode of herpes
zoster, Pneumocystis jirovecii pneumonia, tuberculosis, Kaposi sarcoma, meningitis, or encephalitis. Relative risk calculated using Cox regression.
Time=months since delivery.
doi:10.1371/journal.pone.0019947.g003
Figure 2. Scatterplot of Log10 HIV-1 RNA Level Over Time, by HSV-2 Serostatus at Baseline. Points represent individual measures of log10
HIV-1 RNA levels. Curves represent locally weighted smoothed curves of log10 HIV-1 RNA levels over time, by HSV-2 serostatus. Time=months since
delivery.
doi:10.1371/journal.pone.0019947.g002
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on maternal HIV-1 disease progression in co-infected pregnant
and postpartum women. Given the high mortality rates and poor
health outcomes among HIV-infected women in sub-Saharan
Africa and the high rates of HIV/AIDS-related orphans when
mothers die prematurely, herpes suppressive therapy should be
considered as an additional tool to improve maternal health and
survival among women with HIV-1 and GUD.
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